The importance of drug scheduling in cancer chemotherapy: Etoposide as an example

Stem Cells

Volumn 14, Issue 1, 1996, Pages 18-24

  Hande, Kenneth R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Administration schedule; Bioavailability; Cancer pharmacology; Etoposide; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL CYCLE; DNA STRAND BREAKAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0030071784     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140018     Document Type: Review

References (40)

1. Frei E, Bickers JN, Hewlett JS et al. Dose schedule and antitumor studies of arabinosyl cytosine. Cancer Res 1969;29:1325-1332.
2. Pinedo HM, Zaharko DS, Bull JM et al. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 1977;37:445-450.
3. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM. eds. Cancer Chemotherapy: Principles and Practice. Philadelphia: JB Lippincott, 1990:180-224.
4. Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. Bioessays 1991;13:269-275.
5. Liu LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989;58:351-375.
6. Walker PR, Smith C. Youdale T et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991,51:1078-1085.
7. Lowe SW, Ruley BE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993;74:957-967.
8. Kamesaki S, Kamesaki H, Jorgensen TJ et al. Bcl-2 protein inhibits etoposide-induced apoptosis through its effect on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993;53:4251-4256.
9. Heck MMS. Hittelman AN. Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;85:1086-1090.
10. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990;50:5813-5818.
11. Wolff SN, Grosh WW, Prater K et al. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 1987;19:246-249.
12. Drewinko B, Barlogie B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat Rep 1976;60:1295-1306.
13. Slevin ML, Clark PI, Joel SP et al A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989;7:1333-1340.
14. Clark PI, Slevin NE, Joel SP et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12:1427-1435.
15. Hainsworth JD, Johnson DH, Frazier SR et al. Chronic daily administration of oral etoposide - a Phase I trial. J Clin Oncol 1989;7:396-401.
16. Johnson DH, Greco FA, Strupp D et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a Phase I trial. J Clin Oncol 1990;8:1613-1617.
17. Sessa C, Zucchetti K, Torri V et al. Chronic oral etoposide in small cell lung cancer: clinical and pharmacokinetic results. Ann Oncol 1993;4:553-558.
18. Waits TK, Johnson DH, Hainsworth JD et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a Phase II trial. J Clin Oncol 1992;10:292-296.
19. Hainsworth JD, Johnson DK, Frazier SR et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990;26:818-821.
20. Miller JC, Einhorn LH Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990;17:36-39.
21. Greco FA. Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 1993;19(suppl):35-45.
22. Markman M, Hakes T, Reichman B et al. Phase 11 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992;119:55-57.
23. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-63.
24. Martin M. Lluch A, Casadro A et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:986-991.
25. Calvert AH, Lind MJ, Millward MM et al. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat Rev 1993;19(suppl):27-33.
26. Miller AA, Herndon J, Hollis D et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized Phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13:1871-1879.
27. Hande KR. Etoposide pharmacology. Semin Oncol 1992;19(suppl):3-9.
28. Hande KR, Wedlund PJ, Noone RM et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984;44:379-382.
29. D'Incalci M, Rossi C, Zucchetti M et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986;46:2566-2571.
30. Hande KR, Wolff SN, Greco FA et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990;8:1101-1107.
31. Stewart CF, Pieper JA, Arburk SG et al. Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989;45:49-55.
32. Pashko S, Johnson DH. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer. Pharmacol Econ 1992;1:293-297.
33. Hande KR, Krozely MG, Greco FA et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-377.
34. Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose infusional etoposide in patients with advanced malignancies. Cancer 1994;73:2824-2831.
35. Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide sensitive neoplasms: a Phase I/II study. J Clin Oncol 1993;11:1322-1328.
36. Sarkar M, Higa G, Robbins A et al. Determination of a therapeutic window and a pharmacokinetic pharmacodynamic model for chronic low-dose etoposide Proc Am Soc Clin Oncol 1993;13:138.
37. Kunitoh H, Watanabe K. A Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with lung cancer. J Clin Oncol 1994;12:83-89.
38. Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 1991;325:1682-1687.
39. Nichols CR, Breeded ES, Loehrer PJ et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst. 1993;85:36-40.
40. Bajorin DF, Motzer RJ, Rodriguez E et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst. 1993;85:60-63.